I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Tao Fu Biography and Net Worth

COO of Zai Lab

Tao Fu is our Chief Strategy Officer. Prior to joining Zai Lab, he worked at Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company's corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company and Becton Dickinson.

Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).

What is Tao Fu's net worth?: The estimated net worth of Tao Fu is at least $5.61 million as of September 15th, 2021. Mr. Fu owns 217,500 shares of Zai Lab stock worth more than $5,613,675 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Fu may own. Learn More about Tao Fu's net worth.
How do I contact Tao Fu?: The corporate mailing address for Mr. Fu and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on Tao Fu's contact information.
Has Tao Fu been buying or selling shares of Zai Lab?: Tao Fu has not been actively trading shares of Zai Lab over the course of the past ninety days. Most recently, Tao Fu sold 10,000 shares of the business's stock in a transaction on Thursday, October 28th. The shares were sold at an average price of $105.00, for a transaction totalling $1,050,000.00. Learn More on Tao Fu's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Rafael Amado (President, Head of Global Research and Development), Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 1 times. They purchased a total of 4,000 shares worth more than $119,600.00. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 105,597 shares worth more than $2,125,230.82. The most recent insider tranaction occured on August, 16th when insider Joshua L Smiley sold 4,352 shares worth more than $72,547.84. Insiders at Zai Lab own 13.9% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 8/16/2024.

Tao Fu Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2021	Sell	10,000	$105.00	$1,050,000.00
10/14/2021	Sell	10,000	$102.68	$1,026,800.00
9/30/2021	Sell	10,000	$106.73	$1,067,300.00
9/15/2021	Sell	9,900	$127.86	$1,265,814.00	217,500
8/25/2021	Sell	10,000	$143.03	$1,430,300.00	217,000
7/15/2021	Sell	10,000	$172.82	$1,728,200.00
6/15/2021	Sell	10,000	$165.28	$1,652,800.00	217,000
5/26/2021	Sell	10,000	$159.40	$1,594,000.00	217,000
4/19/2021	Sell	10,000	$162.91	$1,629,100.00	217,000

Tao Fu Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $25.81

$25.66

$26.52

50 Day Range

MA: $26.38

$20.34

$33.18

2 Week Range

Now: $25.81

$13.48

$36.60

Volume

153,712 shs

Average Volume

703,072 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

I was wrong. Dead wrong.

From Porter & Company | Ad